Meghana Keshavan

Meghana Keshavan

Meghana has spent the last year-and-a-half writing about biotech and healthcare for the San Diego Business Journal. Previously, she's worked for Reuters, Crain’s Detroit Business, the Detroit Free Press and WDET, a Detroit-based National Public Radio affiliate. Meghana studied biochemistry and molecular biology at Penn State University and spent five years as a self-described "research peon in a schizophrenia genetics lab."

Follow Meghana Keshavan: Twitter |


Startup crowdsourcing for better clinical trial design

Startup crowdsourcing for better clinical trial design

September 19, 2014 11:52 am by | 0 Comments

Transparency Life Sciences is looking to change up the clinical trial model by introducing opensourcing to the picture. The idea here is to create “more patient-centric, transparent and dramatically less costly clinical…


Industry vet David Socks brings venture firm Frazier Healthcare to Boston

Industry vet David Socks brings venture firm Frazier Healthcare to Boston

September 18, 2014 11:50 am by | 1 Comments

The Seattle- and Bay Area-based venture firm Frazier Healthcare has added industry vet David Socks to its ranks. He’ll be based in Boston, bringing a Massachusetts presence to the healthcare and life sciences-focused…



A nifty map of life sciences companies in Cambridge’s Kendall Square

A nifty map of life sciences companies in Cambridge’s Kendall Square

September 18, 2014 9:33 am by | 0 Comments

There’s no question that Cambridge is known for its hyper-dense concentration of life sciences companies, but the folks over at advisory firm MassGlobal Partners put together a nice infographic that…


Startup using crowdfunding + 3D printing to make faster, cheaper back braces for kids

Startup using crowdfunding + 3D printing to make faster, cheaper back braces for kids

September 18, 2014 6:00 am by | 4 Comments

British startup Andiamo is in the midst of a crowdfunding effort on Indiegogo to develop 3D-printed, custom orthotics for disabled children. It’s working toward a £60,000 – or $100,000(ish) goal -…


J&J launches Neuroscience Catalyst to seed academic spinouts

J&J launches Neuroscience Catalyst to seed academic spinouts

September 17, 2014 12:30 pm by | 0 Comments

There’s a serious dearth of psychiatric drugs under development, but Janssen is taking a gander at speeding up innovation on that front. The project’s called Neuroscience Catalyst. Over the course of…


L.A.’s affluent anti-vaxxers may be behind city’s whooping cough epidemic

L.A.’s affluent anti-vaxxers may be behind city’s whooping cough epidemic

September 17, 2014 6:00 am by | 1 Comments

With the threat of a deadly whooping cough epidemic descending on Los Angeles, the chinks in our post-industrial herd immunity are starting to show – among America’s most affluent. The anti-vaxxer movement…


Startup uses 3D printing tech to create alternative to bone grafts

Startup uses 3D printing tech to create alternative to bone grafts

September 16, 2014 11:42 am by | 0 Comments

A Michigan startup is using 3D printing technology to help surgeons reconstruct skeletal defects – minimizing the need for bone grafts to fill areas with significant missing bone. Tissue Regeneration Systems is developing porous,…



Study of 4,215 orders shows $226 spent per patient on unnecessary care

Study of 4,215 orders shows $226 spent per patient on unnecessary care

September 16, 2014 9:27 am by | 0 Comments

  Doctors that are afraid of legal backlash are much more likely to order unnecessary tests and hospitalization, according to a new study published this week in JAMA Internal Medicine. Defensive…


Epirus’ arthritis biosimilar approval in India shows its international focus

Epirus’ arthritis biosimilar approval in India shows its international focus

September 16, 2014 6:00 am by | 0 Comments

Boston-based Epirus Bioscience has gotten the green light from regulators to market its Remicade biosimilar in India, teaming up with Ranbaxy to market the Johnson & Johnson analogue next year….


Soon-Shiong’s NantBioScience forges anti-cancer partnership with University of Colorado

Soon-Shiong’s NantBioScience forges anti-cancer partnership with University of Colorado

September 15, 2014 10:00 am by | 0 Comments

Given billionaire Patrick Soon-Shiong’s general save-the-world M.O., it’s always worth tracking what his companies are up to. NantBioScience, an offshoot of his Los Angeles startup NantWorks, has partnered up with University of Colorado to  develop protein-targeted…


Scholar Rock raises $20M for its targeted growth factor therapies

Scholar Rock raises $20M for its targeted growth factor therapies

September 15, 2014 7:00 am by | 0 Comments

Targeting the growth factors that influence cell proliferation and differentiation in disease is a pretty “well-trodden” field, but Cambridge biotech Scholar Rock purports to take a new spin on the concept. It’s announced…


A risk analysis of death, put in graphic perspective

A risk analysis of death, put in graphic perspective

September 15, 2014 6:00 am by | 0 Comments

The National Health Service in England has come out with a very cool infographic that helps explain risk to patients. The NHS Atlas of Risk puts conditions or situations into perspective…


A new source for antibiotics found in… the vagina?

A new source for antibiotics found in… the vagina?

September 12, 2014 4:16 pm by | 0 Comments

Researchers have found a fertile source for new antibiotics: Vaginal bacteria. It’s a Darwinian world down there, with “good,” antibiotic-producing bacteria present to combat more malevolent microcritters like MRSA. So when…


Colorectal cancer screening could be whittled down to a drop of blood

Colorectal cancer screening could be whittled down to a drop of blood

September 12, 2014 7:00 am by | 1 Comments

A Belgian startup may offer an alternative to screening colonoscopies - VolitionRx is reporting its single-drop blood test can diagnose 84 percent of colorectal cancers of all stages, with 78 percent specificity….


Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

Feds give Cellerant $47.5M for stem cell treatment that preps for nuclear disaster

September 12, 2014 6:30 am by | 0 Comments

Stem cell therapy is one way the government’s preparing for a nation impacted by nuclear disaster. Cellerant Therapeutics has received $47.5 million from the government to develop its treatment for radiation poisoning….